الفهرس 
Introduction and aim of the studyOnly 14 pages are availabe for public view
 |  | from | 88 |  |  |
| | | from | 88 | | |
Abstract
This study identified a polymorphism 3 kb upstream of IL28B (namely; rs8099917) that is significantly associated with response to PEG-IFN and RBV for patients with chronic genotype 4 HCV infection. It seems likely that the gene product is involved in the innate control of HCV. So we recommend further study of the functional mechanism underlying the IL28B response association, may help to identify patients for whom therapy is likely to be successful.
In our study there was no significant difference between responders and non responders regarding age (P value = 0.857), sex (P value = 0.055), associated disease as HTN (P value = 0.71), DM (P value = 0.299), type of interferon 2a and 2b (P value = 0.461), fibrosis (P value =0.068), viral load (P value =0.855), ALT (P value =0.124), AST(P value =0.588), or BMI (P value =0.378). While there was significant difference between responders and non responders as regarding disease activity (P=0.04) being worsen in non responders.
The TT homozygous of rs8099917 genotype was detected in 54 (43.54%) of overall HCV patients, 42 of them (67.74%) achieved SVR. The GT heterozygous was detected in 48 (38.71%) of HCV patients, SVR was achieved in 9 (14.52%) of them. While, the GG genotype was found in 22 patients and 11 of them only (17.74%) were responders.
In the current study, we have found that Multiple regression analysis identified IL28 B SNP genotype as the only independent predictor of response to SOC therapy.